Plain-English translation of NCT07502768 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two drugs— and —to see if they work together to treat NK/T-cell lymphoma, a rare blood cancer that has come back or stopped responding to standard chemotherapy. Researchers want to find the best dose of this medication combination and measure how many patients see their cancer improve.
NK/T-cell lymphoma is a difficult cancer to treat, especially when it returns or stops responding to chemotherapy. This trial exists because doctors need better treatment options for these patients, and early research suggests that this medication combination might work in ways that could help.
You likely qualify if…
You likely don't qualify if…
You would receive as an intravenous infusion every three weeks and take as an oral tablet twice daily. The first phase of the trial focuses on finding the safest dose, while the second phase tests whether the medication works. You'll have regular imaging scans and blood tests to monitor your cancer and watch for side effects, and treatment continues until your cancer stops responding, you experience unacceptable side effects, or you choose to stop.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China